Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a primary liver or bile duct cancer confirmed by a pathology test, OR liver tumours that have spread from another cancer (not lymphoma) confirmed by pathology, OR liver tumours that look like spread cancer on scans in someone already known to have cancer, OR a type of liver cancer called hepatocellular carcinoma diagnosed through scan findings, elevated AFP blood levels, and a history of liver scarring or chronic hepatitis.
- People who have 5 or fewer liver tumours that can be measured on a contrast-enhanced CT or MRI scan taken within the last 90 days.
- People whose liver tumour(s) measure 25 cm or less in size.
- People who have cancer outside the liver, as long as the liver disease is considered to be the most life-threatening part of their illness.
- People who have no medical reasons preventing them from having radiotherapy.
- People whose cancer has been assessed as not suitable for surgery or surgical removal.
- People who score between 0 and 3 on a standard health and activity scale used by doctors (confirm with trial site).
- People aged over 18.
- People who are receiving certain cancer medicines, including multikinase inhibitors or immunotherapy (note: specific timing rules around radiation apply — confirm with trial site).
- People who have previously had liver surgery or tumour-destroying treatments.
- People who have finished chemotherapy at least 2 weeks before starting radiation, and who are not planned to restart chemotherapy for at least 1 week after treatment ends (or at least 4 weeks for a specific type called anthracyclines).
- People with a life expectancy of more than 6 months.
- People who are able and willing to use adequate contraception (applies to women who could become pregnant and to male participants).
Who may not be able to join:
- People with severe liver scarring or liver failure, defined by a medical scoring system called Child-Pugh above B7 (confirm with trial site).
- People who have previously had radiotherapy to the same area of the body in a way that would cause the radiation fields to overlap with this treatment.
- People with serious ongoing health conditions that limit life expectancy to less than 6 months.
- People with active hepatitis or significant liver failure (people with treated hepatitis may still be eligible).
- People who are pregnant, breastfeeding, or who could become pregnant and are unwilling or unable to use an acceptable form of contraception, as well as sexually active men who are unwilling or unable to use contraception — this is because the treatment may harm an unborn baby.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Michael Lock, MD, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phone: 519-685-8500
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall survival; Treated lesion progression
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.